Dr. Gregory J. Tobin

Dr. Tobin has led research and technical programs at BMI since 1999.  Dr. Tobin has significant experience in project direction and management; design, planning, and execution of research projects; personnel management; coordination of multi-site studies and development of research facilities.  Dr. Tobin fosters a highly interactive research and development group to apply the Company’s proprietary technology, Immune Refocusing Technology, to the design of antigens that induce broader protection against heterologous challenge.  Dr. Tobin continues to maintain research projects and interests in the development of broadened vaccines against HIV-1, influenza virus, rhinovirus, malaria, dengue virus, and non-typeable hemophilus influenza.

Prior to joining BMI, Dr. Tobin was a Senior Scientist and Group Leader (Gene Expression Regulation Group) for SAIC-Frederick at the National Cancer Institute.  While at the NCI, Dr. Tobin led projects related to development of virus-like particle (VLP) based vaccines for HIV-1, optimization of recombinant protein expression, development of animal models for AIDS and cancer, and investigations into the pathobiology and molecular mechanisms of bovine immunodeficiency virus (BIV) and visna virus.  Dr. Tobin was a post-doctoral scientist applying transgenic mouse models to the understanding of oncogenesis in the laboratory of Dr. Terry Van Dyke.  During his doctoral research, Dr. Tobin studied the replication of poliovirus with Dr. J. Bert Flanegan at the University of Florida.  Prior to graduate studies, Dr. Tobin gained valuable insight into virology and research methods in the University of Virginia laboratory of Dr. Jay C. Brown and William W. Newcomb.

Published works of Dr. Tobin (a partial list)

Pan K, J Long, GJ Tobin, PL Nara and MW Deem. A Non-equilibrium Model of the Evolution of Charged Amino Acid Residues in H3 Hemagglutinin, In press

Bushnell RV, JK Tobin, J Long, S. Nara, LA Moser, S. Schultz-Cherry, PL Nara, and GJ Tobin. Stimulation of humoral responses in the influenza-guinea pig infection model. Virology J. In press

Eguchi-Ogawa, T, N Wertz, X-Z Sun, F Puim, H Uenishi, K Wells, P Chardon, GJ Tobin & JE. Butler Antibody repertoire development in fetal and neonatal piglets. XI. The relationship of VDJ usage and the genomic organization of the variable heavy chain locus. J. Immunol 184:3734-42 (2010)

Nara, P.L., Nara D, Chaudhuri, AR., Lin G, and Tobin, GJ Perspectives on advancing the field of vaccinology at the wild, domestic, laboratory, veterinary and human interface: Not missing the opportunities. Vaccine 26:6200-11 (2008).

Tobin, GJ, JD Trujillo, RV Bushnell, G Lin, AR Chaudhuri, J Long, J Barrera, L Pena, MJ Grubman and PL Nara. Deceptive Imprinting and Immune Refocusing in Vaccine Design. Vaccine.  26:6189-99. (2008) 

Yang, Q.E., S.E. Fong, K. Li K, M.A. Gonda, and G.J. Tobin. Ex vivo expanded murine bone marrow cells with a multiple cytokine cocktail retain long-term hematopoietic reconstitution potentials. Med Sci Monit. BR154-161, 2005.

Chang C, D. Magracheva, S. Kozlov, S. Fong, G. Tobin, S. Kotenko, A. Wlodawer, and A. Zdanov A. Crystal structure of interleukin-19 defines a new subfamily of helical cytokines. J Biol Chem. 278(5):3308-13, 2003.

Pletnev S, Magracheva E, Kozlov S, Tobin GJ, Kotenko S, Wlodawer A, and Zdanov A. Characterization of Recombinant Extracellular Domains of Human Interleukin-20 Receptors and Their Complexes With Interleukin-19 and Interleukin-20. Biochemistry 42:12617-24. (2003).

Forns X, S. U. Emerson.  G. J. Tobin, I.K. Mushahwar, R.H. Purcell and J. Bukh DNA immunization of  mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface.  Vaccine. 17(15-16):1992-2002, 1999.

Howard, O. M. Z., C. Winkler, M. Carrington, S. O'Brien, G. J. Tobin, and M. Dean.  The effect of CCR5 mutations on ligand signaling and HIV-1 entry. J Biol Chem. 274(23):16228-34. 1999.

Kervinen, J., G. J. Tobin, J,. Costa, D.S. Waugh, A. Wlodawer, and A. Zadnov.  Crystal structure of plant aspartyl proteinase prophytepsin: the modes of inactivation and vacuolar targeting. EMBO J. 18(14):3947-55, 1999.

Glathe. S., J. Kervinen, M. Nimtz, G.H. Li, G.J. Tobin, T.D. Copeland, D.A. Ashford, A. Wlodawer, J. Costa. Transport and activation of the vacuolar aspartic proteinase phytepsin in barley (Hordeum vulgare L.). J Biol Chem 273:31230-6, 1998.

Rafnar, B., G.J. Tobin, K. Nagashima, M.A. Gonda, E. Gunnarsson, O.S. Andresson, G. Georgsson, and S. Torsteinsdottir.  Immune response to the visna virus Gag and Env proteins expressed in insect cells. Virus Res 53:107-20, 1998.

Gonda, M.A., J.K. Battles, S.E. Fong, D.G. Luther, T.G. Snider, K.J. Garvey, L. Feigenbaum, and G.J.Tobin. Biology of the bovine immunodeficiency virus.  In Jembrana Disease and the Bovine Lentiviruses, p103-109, pub. Australian Center for International Agricultural Research, 1997.

Fong, S.E., J.D. Greenwood, J.C. Williamson, D. Derse, L.A. Pallansch, T. Copeland, G.J. Tobin, L. Rasmussen, A. Mentzer, K. Nagashima, and M.A. Gonda.  Bovine immunodeficiency virus tat gene: cloning of two distinct cDNAs and identification, characterization, and immunolocalization of the tat gene products.  Virology. 233:339-57, 1997.

Tobin, G.J., G. Li, K. Nagashima, S.E. Fong, and M.A. Gonda.  Chimeric HIV-1 like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities.  Virology 236:307-315, 1997.

Tobin, G.J., G.H. Li, J. C. Williamson, K. Nagashima, and M.A. Gonda.  Immunologic and ultrastructural characterization of human immunodeficiency virus type 1 pseudovirions containing Gag and Env precursor proteins engineered in insect cells.  Methods: A Companion to Methods in Enzymology. 10:208-218, 1996.

Tobin, G.J., K. Nagashima, and M.A. Gonda.   Use of the particle-forming properties of the HIV Gag precursor for packaging additional viral epitopes into pseudovirions produced in the baculovirus-insect cell expression system.  Intervirology 39:40-48, 1996.

Tobin, G.J., W.E. Ennis, D. Clanton, and M.A. Gonda.  Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell-based assay.  Antiviral Research 33:21-31, 1996.

Tobin, G.J., J.K. Battles, L. Rasmussen, and M.A. Gonda.  Assembly of recombinant retroviral Gag precursors into pseudovirions in the baculovirus-insect cell expression system.  In Methods in Molecular Genetics, Vol. 7, Molecular Virology.  K.W. Adolph, ed.  Academic Press, Orlando, pp. 237-253, 1995.

Walder, R., Z. Kalvatchev, G.J. Tobin, M.N. Barrios, D.J. Garzaro, and M.A. Gonda.  Possible role of bovine immunodeficiency virus in bovine paraplegic syndrome:       evidence from immunochemical, virological and seroprevelance studies.  Res. Virol., 146:313-323, 1995.

Gonda,M.A., D.G. Luther, S.E. Fong, and G.J. Tobin.  Bovine immunodeficiency virus: molecular biology and virus-host interactions.  Virus Res., 32:155-181, 1994. Andrésson, Ó.S., J.E. Elser, G. Georgsson, G.J. Tobin, J.D. Greenwood, M.A. Gonda, V. Andrésdottir, P.A. Pálsson, and G. Pétursson.  Pathogenic proviral molecular clone of neurovirulent visna virus.  Ann. N.Y. Acad. Sci., 724:133-139, 1994.

Gonda, M.A., S.E. Fong, and G.J. Tobin. Bovine immunodeficiency virus: emerging biology of a nonacute pathogenic lentivirus of cattle.  Food Microbiol., 11:149-160, 1994.

Tobin, G.J., R.C. Sowder II, D. Fabris, M.Y. Hu, J.K. Battles, C. Fenselau, L.E. Henderson, and M.A. Gonda.  Amino acid sequence analysis of the proteolytic cleavage products of the bovine immunodeficiency virus Gag precursor polypeptide.  J. Virol., 68:7620-7627, 1994.

Andrésson, Ó.S., J.E. Elser, G.J. Tobin, J.D. Greenwood, M.A. Gonda, G., Georgsson, V. Andrésdóttir, E. Benediktsdóttir, H.M. Carlsdóttir, E.O. Mäntylä, B. Rafnar, P.A. Pálsson, J.W. Casey, and G. Pétursson.  Nucleotide sequence and biological properties of a pathogenic proviral molecular clone of neurovirulent visna virus.  Virology, 193:89-105, 1993.

Chen, J., G.J. Tobin, J. Pipas, and T. Van Dyke. T antigen mutant activities in transgenic mice: Roles of p53 and pRB binding in tumorigenesis of the choroid plexus.  Oncogene, 7:1167-75, 1992.

Battles, J.K., M.Y. Hu, L. Rasmussen, G.J. Tobin, and M.A. Gonda.  Immunological characterization of the gag gene products of bovine immunodeficiency virus.  J. Virol., 66:6868-6877, 1992.

Flanegan, J.B., G.J. Tobin, M.S. Oberste, B.J. Morasco, D.C. Young, and P.S. Collis.  Mechanism of picornavirus negative strand RNA synthesis and the self-catalyzed covalent linkage of VPg to RNA. In New Aspects of Positive Strand RNA Viruses.  M.A. Brinton and F.X. Heinz, eds.  American Society for Microbiology, Washington, DC, Chapter 9, pp. 55-59, 1990.

Tobin, G.J.  Poliovirus Replication.  Doctoral Dissertation, University of Florida, 1989.

Tobin, G.J., D.C. Young, and J.B. Flanegan.  Self-catalyzed linkage of poliovirus terminal protein VPg to poliovirus RNA.  Cell, 59:511-519, 1989.

Oberste, M.S., G.J. Tobin, and J.B. Flanegan.  RNA binding and replication by the poliovirus RNA polymerase.  J. Cell. Biochem. suppl. 12D:42, 1988.

Flanegan, J.B., D.C. Young, G.J. Tobin, M.M. Stokes, C.D. Murphy, and M.S. Oberste.  Mechanism of RNA replication by the poliovirus RNA polymerase, HeLa cell host factor and Vpg.  In Positive Strand RNA Viruses, UCLA Symposia on Molecular and Cellular Biology, New Series.  R. Rueckert and M. Brinton, eds.  Alan R. Liss, New York, Vol. 54, pp. 273-284, 1987.

Young, D.C., G.J. Tobin, and J.B. Flanegan.  Characterization of product RNA synthesized in vitro by poliovirus RNA polymerase purified by chromatography on hydroxyapatite or poly(U)-sepharose.  J. Virol., 61:611-614, 1987.

Young, D.C., B.M. Dunn, G.J. Tobin, and J.B. Flanegan.  Anti-Vpg antibody immunoprecipitation of product RNA synthesized in vitro by the poliovirus polymerase and host factor is mediated by VPg on the poliovirion RNA template.  J. Virol., 55:715-723, 1986.

Newcomb, W.W., G.J. Tobin, J.J. McGowan, and J.C. Brown.  In vitro reassembly of vesicular stomatitis virus skeletons. J. Virol., 41:1055-1062, 1982.